Invizius, which has developed technology to help reduce the high death rate among patients using dialysis and other extra-corporeal treatments, secured the seven-figure sum from a consortium led by asset manager Mercia.
This investment allows us to take a big step towards this, and we are delighted to have won the backing of a consortium of smart, well-funded investors...Richard Boyd, co-founder and chief executive, Invizius
The funding boost will support pre-clinical testing and manufacturing of the medtech’s product, and help it prepare to enter clinical trials. It plans to hold a further funding round within 18 months.
The spin-out believes its technology, which stems from research by co-founder and chief technology officer Andy Herbert, can reduce the “huge” death toll from cardiovascular disease among long-term dialysis patients.
The technology can also be used in conjunction with devices such as heart and lung machines, stents and grafts or in organ and cell transplants...